fuculose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6857362 |
| CHEBI ID | 17617 |
| SCHEMBL ID | 12189710 |
| MeSH ID | M0510001 |
| Synonym |
|---|
| 6-deoxy-l-lyxo-hex-2-ulose |
| CHEBI:17617 |
| C01721 |
| 6-deoxy-l-tagatose |
| fuculose |
| 13074-08-3 |
| L-FUCULOSE , |
| (3r,4r,5s)-1,3,4,5-tetrahydroxyhexan-2-one |
| SCHEMBL12189710 |
| l-tagatose, 6-deoxy- |
| CVU , |
| l-fuculose open form |
| 6-deoxy l-tagatose |
| QZNPNKJXABGCRC-LFRDXLMFSA-N |
| AKOS030254823 |
| Q3047391 |
| l-fuculose (1m in water) |
L-Fuculose is a valuable rare sugar that is used to treat a variety of ailments, including HIV, cancer, Hepatitis B, human lysosomal disease (fucosidosis), and cardio-protective medications.
| Excerpt | Reference | Relevance |
|---|---|---|
| "l-Fuculose is a valuable rare sugar that is used to treat a variety of ailments, including HIV, cancer, Hepatitis B, human lysosomal disease (fucosidosis), and cardio-protective medications. " | ( Characterization of l-fucose isomerase from Paenibacillus rhizosphaerae to produce l-fuculose from hydrolyzed fucoidan and commercial fucose. Iqbal, MW; Mahmood, S; Mu, W; Ni, D; Qi, X; Riaz, T; Zhang, W, 2023) | 1.86 |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| deoxyketohexose | Any ketohexose having at least one hydroxy group replaced by hydrogen. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Fucose and Rhamnose Degradation | 12 | 18 |
| superpathway of fucose and rhamnose degradation | 11 | 41 |
| fucose degradation | 4 | 14 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||